ClinicalTrials.gg
Active, not recruitingNCT05222906LEAP2MONOUpdated Jul 13, 2026

Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3

A Phase 3 interventional study of Venglustat and imiglucerase in Gaucher's Disease Type III, sponsored by Sanofi. Active, not recruiting at 22 sites in 11 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
43
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Gaucher Disease by Sanofi — 2 open to participants now, 4 under way, 2 of them phase 3. Gaucher Disease · Sanofi.

Enrollment
5th of 19
43 · median 26
Started
2022
the only one that year
Phase 3
7 of 24
1 open now
Registered
18th of 24
by date

Among the 24 studies in Gaucher Disease by Sanofi, this one is the 5th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2022, is one of 7 in phase 3, and was the 18th registered.

Gaucher Disease

177 studies on the registry are indexed under Gaucher Disease; 41 are open to participants now.

Browse Gaucher Disease studies →

Open to participants now

2 of the 24 studies in Gaucher Disease by Sanofi are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 26 Gaucher Disease studies recruiting now, 11 (42%) set no upper age limit and 11 (42%) stop at 75 or younger; 15 take children under 18; 4 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Gaucher Disease by Sanofi, or all of them as a file.
02

Study summary

This is a parallel arm, Phase 3, double-blind, double-dummy, active-comparator, 2 arm study to evaluate the efficacy and safety of daily oral venglustat versus intravenous Cerezyme infusions every two weeks for improvement or stabilization of the neurological manifestations and maintenance of systemic disease stability in participants aged ≥12 and \<18 years and adult patients with Gaucher disease Type 3 (GD3) who have been treated with Enzyme Replacement Therapy (ERT) for at least 3 years.

Read the detailed description

Screening period: 45 days

Double blind, double-dummy, primary analysis treatment period: 52 weeks

Open label extended treatment period: minimum of 52 weeks due to a common study end of treatment date

Follow up phone call: 30-37 days after end of treatment

03

Conditions studied

  • Gaucher's Disease Type III

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant has received ERT (Cerezyme or other ERT; as deemed appropriate by local regulations) for at least 3 years prior to enrollment, on a stable dose for at least 6 months, is deemed clinically stable for at least 1 year by the Investigator and is within the therapeutic goals as all of the following:

    • level of ≥11.0 g/dL for females and ≥12.0 g/dL for males
    • count ≥100 000/mm3
    • Spleen volume \<10 multiples of normal (MN)
    • Liver volume \<1.5 MN
    • No bone crisis and free of symptomatic bone disease such as bone pain attributable to osteonecrosis and/or pathological fractures within 3 months prior to screening
  • Adult participant is ≥18 years of age
  • Pediatric participant is ≥12 years \<18 years of age
  • The participant has a clinical diagnosis of GD3 and a documented deficiency of acid beta-glucosidase activity confirming this diagnosis.
  • The participant has a modified SARA score of 1 or above.
  • The presence of gaze palsy, predominantly horizontal, with slow or absent saccades.
  • If the participant has a history of seizures, they are well controlled under appropriate medication not identified as a strong or moderate inducer or inhibitor of .
  • Participants ≥ 30 kg of weight
  • for sexually active male or female participants; not pregnant or breastfeeding; no sperm donating for male participant
  • Signed written informed assent/consent

Exclusion criteria

Exclusion Criteria:

  • The participant is blood transfusion-dependent.
  • Prior esophageal varices or liver infarction or current liver enzymes ( [ALT]/ aspartate aminotransferase [AST]) or total >2 times the , unless the participant has a diagnosis of Gilbert Syndrome.
  • The participant has any disease, other than GD, including cardiovascular (congenital cardiac defect, coronary artery disease, valve disease or left sided heart failure; clinically significant arrhythmias or conduction defect), hepatic, gastrointestinal, pulmonary, neurologic, endocrine, metabolic (eg, hypokalemia, hypomagnesemia) or psychiatric disease, other medical conditions, or serious intercurrent illnesses that may preclude participation in the opinion of the Investigator.
  • The participant has renal insufficiency, as defined by an estimated \<30 mL/min/1.73m2 at the screening visit.
  • The participant has a history of cancer, except for basal cell carcinoma.
  • The participant has progressive myoclonic epilepsy.
  • The participant is pregnant (has a positive serum beta-human chronic gonadotropin [β-hCG]) or lactating.
  • The participant requires use of invasive ventilatory support.
  • The participant requires use of noninvasive ventilator support while awake for longer than 12 hours daily.
  • The participant is scheduled for in-patient hospitalization including elective surgery, during the study.
  • The participant has had a major organ transplant (eg, bone marrow or liver).
  • A history of drug and/or alcohol abuse within the past year prior to the screening visit.
  • Chaperone therapy within 6 months, substrate reduction therapy other than venglustat within 6 months or venglustat substrate reduction therapy prior to enrollment.
  • Exposure to any drug within the last 30 days or 5 half-lives from screening, whichever is longer.
  • The participant has received strong or moderate inducers or inhibitors of within 14 days or 5 half-lives from screening, whichever is longer, prior to screening. This also includes the consumption of grapefruit, grapefruit juice, or grapefruit containing products within 72 hours of starting venglustat. The participant is unwilling to abstain from consumption of grapefruit, grapefruit juice, or grapefruit containing products for the duration of the treatment period.
  • The participant, in the opinion of the investigator, is unable to adhere to the requirements of the study or unable to undergo study assessments (eg, for MRI).
  • Type of participant and disease characteristic: the participant has had a total splenectomy prior to enrollment. The patient had a partial splenectomy within 3 years prior to randomization.
  • Participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures
  • Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator, contraindicates participation in the study

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Venglustat

    Venglustat

    Drug: Venglustat

  • Active comparator
    Cerezyme

    Cerezyme

    Drug: imiglucerase

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Scale for Assessment and Rating of Ataxia (SARA) modified total score

    Time frame: From baseline to Week 52

  2. Change in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) total scale index score

    Time frame: From baseline to Week 52

Secondary outcomes

  1. Percent change in spleen volume

    Time frame: From baseline to Week 52

  2. Percent change in liver volume

    Time frame: From baseline to Week 52

  3. Change in hemoglobin level

    Time frame: From baseline to Week 52

  4. Percent change in platelet count

    Time frame: From baseline to Week 52

  5. Percent change in CSF GL-1 and lyso-GL-1 levels

    Time frame: From baseline to Week 52

  6. Percent change in plasma GL-1 and lyso-GL-1 levels

    Time frame: From baseline to Week 52

  7. Number of patients with treatment emergent adverse events (TEAEs)/ serious adverse events (SAEs)/ adverse events of special interest (AESIs)

    Time frame: From baseline to max of 4.5 years

  8. Change in score of Beck Depression Inventory II (BDI-II) during the treatment-emergent period (for participants 13 years of age and above at baseline)

    Time frame: From baseline to Week 52

  9. Change in Patient Health Questionnaire 9 (PHQ-9) during the treatment-emergent period (for participants 12 years of age at baseline)

    Time frame: From baseline to Week 52

07

Study locations

22 sites
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Oct 2025, 41 months.

Of 11 phase 3 interventional studies under Gaucher Disease, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 57. This study's 41 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2022
First posted
Feb 3, 2022
StartActual
Apr 18, 2022
Primary completionActual
Oct 2, 2025
CompletionEst.
Oct 30, 2026
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05222906
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Feb 3, 2022
Start date
Apr 18, 2022
Primary completion
Oct 2, 2025
Completion
Oct 30, 2026 (estimated)
Last update
Jul 13, 2026

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Venglustat

Start the discussion